A new TRISPR screening tool on the genome scale stimulates natural killer cells to fight cancer

Natural Killer (NK) cells have become much better to kill cancer cells after scientists have removed target targets identified by a new CRISPR screening tool on the genome level. Moreover, according to new research from the University of Texas MD Anderson Cancer Center.

The study. Similarly, published today in Cancer cell, Opens new ways to discover approaches to improve the antitumoral activity of NK cell therapies NK receptors of the chimerical antigen (CAR) against several types of cancer via precise, a complete CRISPR discovery platform optimized for primary human NK cells.

Edition of targeted genes is a powerful tool for improving the anti -cancer activity of NK cells. Nevertheless, The precise is more than a screening tool. Meanwhile, It is a roadmap that reveals how tumors remove our cells. In addition, new trispr screening tool genome how to reintrrange cells from the NK car to withstand these pressures on many types of cancer. For example, “”

Katy Rezvani, MD, Ph.D.. corresponding author, Professor of transplantation of stem cells and cell therapy and vice-president and head of the Institute for Discovery and Innovation of Cell therapy

The research was led by GRESSVANI with the first authors of CO Alexander Biederstaedt, MD, formerly Postdoc in the Rezvani laboratory and now with the Munich Technical University and Rafet Basar, MD, PH.D., assistant professor for stem cells and cell therapy.

Using precisely. which was developed by the research team, the investigators revealed several control points and tracks which control the activity of NK cells in the face of the pressures found in the environment surrounding a tumor. This tumor microenvironment tends to have many factors removing immune activity.

The modification new trispr screening tool genome of these targets has strengthened the function of innate NK cells. mediated by the coach, an improvement in the metabolic form, an increased pro-inflammatory cytokines production and the cytotoxic NK subset extended in cancer models which no longer responded to treatment.

While the study highlights three validated targets – Med12, Arih2 et CCNC -Meaning extends far beyond a single gene. Precise provides a impartial card for NK cell regulators which can be priority. edited and combined to design more effective car therapies.

In the study, researchers have validated the best targets in vain Using several tumor models and under defined immune stressors. Some regulators. such as Med12 et CCNCcross with known ways in T -cell biology, while others, including Arih2seem specific to the NK, emphasizing the value of a platform built for the NK cells themselves.

“This has given us a significant overview of the next generation of cell therapies new trispr screening tool genome that can be more powerful. precise and cancer resistant. Rezvani said.

The Rezvani laboratory has led progress in modified NK cell therapy. has provided car approaches to clinical trials for patients with hematological and solid advanced tumors. Thanks to the Institute for Discovery. Innovation of Cell therapy, UNZVANI and its team will continue to develop and advance impactful cellular therapies for patients in need. Current results will be essential to further improve the efficiency and activity of car cells for more types of cancer.